Compare Recursion Pharmaceuticals Inc (RXRX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Spotify Technology — how do they compare? Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B), while Spotify Technology trades at $538.87 (market cap $108.22B). The key difference: Spotify Technology is far larger — about 50.6× Recursion Pharmaceuticals Inc's market cap, and Spotify Technology is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Spotify Technology for 111 Days on average.
| RXRX | SPOT | |
|---|---|---|
Market Cap | $2.14B | $108.22B |
Volume | 30,789,535 | 1,655,796 |
Sector | Health | Media |
52-Week High | $6.79 | $692.04 |
52-Week Low | $2.84 | $412.75 |
Typical Hold Time | 22 Days | 111 Days |
Enterprise Value | $1.66B | $98.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish technical signals from moving averages. The company demonstrates robust fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income reaching $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst consensus remains overwhelmingly positive with 62% buy ratings and a $608.18 price target representing 19% upside potential.
The outlook remains favorable with projected 2026 revenue of $18.1B and net income of $3.3B, though risks include competitive pressures in streaming and recent stock volatility. Key catalysts include Q3 2026 earnings release on October 22, 2026, and continued gross margin expansion from 32.8% currently. Institutional sentiment appears constructive given the strong buy-side analyst coverage and improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
